Myelodysplastic syndrome (MDS)
- Risk-stratify by cytopenias, blasts + genetics
- Low-risk disease focuses on anemia/cytopenia support
- ESA/luspatercept or other subtype-directed therapy may help
- Higher-risk disease often uses hypomethylating therapy
- Allogeneic transplant is the only curative option
- Avoid transfusion iron overload over time
Use at a glance
- Risk-stratify by cytopenias, blasts + genetics
Escalation / refractory disease
- ESA/luspatercept or other subtype-directed therapy may help
- Allogeneic transplant is the only curative option
Practical pearls
- Low-risk disease focuses on anemia/cytopenia support
Safety / pitfalls
- Higher-risk disease often uses hypomethylating therapy
- Avoid transfusion iron overload over time
Self-check
- What guides MDS risk stratification?
Cytopenias, blasts and genetics. - What complication should be avoided with MDS transfusions over time?
Iron overload.
Drugs used for this (1)
All clinical uses · Open Myelodysplastic syndrome (MDS) in the interactive console ↗